ClinicalTrials.gg
RecruitingNCT05054361MAIT-DT1Updated Oct 27, 2026

Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children

An observational study in Type1diabetes, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 2 sites in France. Open to participants aged 12 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.
Updated Oct 27, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
180
Ages
12 Months to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 271 studies in Diabetes Mellitus, Type 1 with a site in France — 39 open to participants now, 45 under way, 8 of them phase 3. Diabetes Mellitus, Type 1 · France.

Planned enrollment
35th of 78
180 · median 153
Started
2022
with 13 others
Observational
78 of 271
22 open now
Primary completion
2027-08
later than 21 of 44 live
Registered
200th of 271
by date

Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, this one is the 35th largest by planned enrollment of the 78 observational ones that give a count, is one of 14 that started in 2022, is one of 78 observational ones, reaches primary completion later than 21 of the 44 other live ones, and was the 200th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

39 of the 271 studies in Diabetes Mellitus, Type 1 with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 12 Months to 15 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies in Diabetes Mellitus, Type 1 with a site in France, or all of them as a file.
02

Study summary

To investigate in a prospective way changes in Mucosal-Associated Invariant T (MAIT) cells frequency, phenotype and function in link with the gut microbiota, gut integrity and the presence of Coxsackie virus B in two cohorts of pediatric patients: patients with a high genetic risk of type 1 diabetes and pediatric patients with recently diagnosed T1D by comparison with control subjects

Tasks:

  1. To measure blood MAIT cells frequency, phenotype and function in the three cohorts
  2. To analyze gut microbiota and the presence of Coxsackie B enterovirus (CVB) and their impact on MAIT cell function
  3. To evaluate gut integrity and analyze the gut mucosa
  4. To integrate all the data obtained with T1D development and evolution
Read the detailed description

Subjects: Multi study. Subjects will be included in the pediatric diabetes and endocrinology unit in Necker Sick children hospital and in the pediatric unit of ANTONY hospital.

  • Recent-onset (RO) n=40: New onset patients will be included shortly after diagnosis.
  • At risk (AR) cohort n=70: Routinely screened siblings of T1D patients previously tested positive for HLA DR3 and DR4 will be asked to be a part of the study.
  • Control (C) cohort (n=50): Control subjects will be patients consulting at Necker Hospital for endocrine testing
  • Control for Endoscopy (CE) n= 20: patients consulting at Necker Hospital or at Antony hospital for UGI endoscopy

Analysis:

MAIT cell analysis: For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression. Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.

Gut microbiota analysis: Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.

Coxsackie virus B (CVB) infection status: Specific antibodies against coxsackie virus B and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by q-PCR and immunochemistry will be performed on a subset of patients.

Gut integrity: the investigators will assess the permeability of the intestine using the Lactulose-Mannitol test in a sub sample of RO, RD and AR groups (> 5 years of age, n=20). In brief after an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours after ingestion.

Gut mucosa analysis: In a subset of patients (without celiac disease as determined by the dosage of antibodies against transglutaminase), duodenal biopsies will be obtained during an IUG endoscopy . Duodenal biopsy will be performed in RD subjects older than 8 years of age and in CE subjects older than 4 years of age. These biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.

Based on previous study, the sample size should allow statistical differences between AR, RO and C groups. The investigators anticipate to observe blood MAIT cell abnormalities in RO patients and some at risk children after seroconversion but before diabetes onset. This new data will strengthen our predictive model (see preliminary data). Since MAIT cells recognize bacterial ligand we hypothesize that MAIT cells alteration could occur in parallel with microbiota changes and/or CVB infection. The investigators anticipate observing gut mucosa abnormalities in RO children and the severity of these abnormalities may correlate with the level of MAIT cells defect and the presence of CVB infection. The investigators expect to demonstrate that MAIT cells represent a new biomarker of progression toward diabetes as well as a functional immune marker of the aggressiveness of the autoimmune disease. As such this study could determine the accurate therapeutic window for preventive strategies based on MAIT cells manipulation.

03

Conditions studied

  • Type1diabetes
04

Who can participate

Ages eligible
12 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Study population: patients recently diagnosed with type 1 diabetes and patients with a high risk of type 1 diabetes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Recent onset group

  • age > 12 months and \< 15 years
  • recently diagnosed type 1 diabetes according ISPAD criteria

At risk subjects:

  • age > 12 months and \< 15 years
  • siblings of type 1 diabetic patient
  • HLA DR3 and DR4 positive

Control subjects:

  • age > 12 months and \< 15 years
  • no HLA associated with high risk type 1 diabetes
  • no antibodies against pancreas antigenes

Control subjects for UGI endoscopy:

  • age > 12 months and \< 15 years
  • suspicion of coeliac disease or gastritis

Exclusion criteria

Exclusion Criteria:

For all groups:

  • no health care insurance
  • parents or tutors unable to sign the consent
  • personal history of disease and/or inflammatory disease except from T1D for RD and CE groups
  • use of during the month before inclusion
  • pregnant subjects
  • medical of anesthetic topics

For control subjects for UGI endoscopy control and Recent onset-endoscopy group:

  • age below 8 years for Recent onset-endoscopy group
  • age below 4 for UGI endoscopy control group
  • cardiac or respiratory insufficiency, cardiac rhythm disorders, coagulation disease, patients treated with anticoagulant or antiaggregant drug
  • history of allergy to anesthetic drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • recent onset patients

    patients with recently diagnosed type 1 diabetes

    Diagnostic Test: MAIT cells analysis · Diagnostic Test: MAIT cytokines production analysis · Diagnostic Test: Lactulose/Mannitol Test · Procedure: UGI Endoscopy · Diagnostic Test: Coxsackie virus B infection status

  • at risk patients

    patients with a high genetic risk type 1 diabetes

    Diagnostic Test: MAIT cells analysis · Diagnostic Test: MAIT cytokines production analysis · Diagnostic Test: Lactulose/Mannitol Test · Diagnostic Test: Coxsackie virus B infection status

  • control subjects

    control patients (no risk of type 1 diabetes and no diagnosed type 1 diabetes)

    Diagnostic Test: MAIT cells analysis · Diagnostic Test: MAIT cytokines production analysis · Diagnostic Test: Lactulose/Mannitol Test · Diagnostic Test: Coxsackie virus B infection status

  • control subjects for endoscopy

    patients without type 1 diabetes requiring UGI endoscopy for any medical reason

    Diagnostic Test: MAIT cells analysis · Diagnostic Test: MAIT cytokines production analysis · Procedure: UGI Endoscopy · Diagnostic Test: Coxsackie virus B infection status

Interventions

  • Diagnostic testMAIT cells analysis

    For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.

  • Diagnostic testMAIT cytokines production analysis

    Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.

  • Diagnostic testLactulose/Mannitol Test

    After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.

  • ProcedureUGI Endoscopy

    Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.

  • Diagnostic testCoxsackie virus B infection status

    Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.

  • Diagnostic testCoxsackie virus B infection status

    Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.

06

What researchers measure

Primary outcomes

  1. blood MAIT cells frequency

    percentage of MAIT cells in the peripheral blood

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

Secondary outcomes

  1. MAIT cells membrane markers analysis

    CD25 positive cells in percentage, CD69 positive cells in percentage, CD44 positive cells in percentage, PD1 positive cells in percentage , KLRG1 positive cells in percentage, TIM3 positive cells in percentage

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

  2. Cytokines production in the cytoplasm of the MAIT

    Antibodies against IL- 2 , IFN-y, TNF-α, IL-2, IL-10, IL-13, IL-17 and granzyme B expressed in Cells %

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

  3. MAIT cell ligands measurements

    Percentage of MAIT cells activated in vitro when cultivated in presence of subject stool sample

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

  4. Presence of CVB in the stools

    CVB specific ARN detection in subjects stools samples by qPCR

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

  5. Blood immunoglobulins against CVB infection statu

    Specific antibodies (Ig G) against CVB measurements in patients blood sample

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

  6. Measurement of intestinal gut mucosal permeability

    Assessing the permeability of the intestine using the Lactulose-Mannitol test. Concentration of lactulose and manitol in subjects urine samples in mg/dl

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

  7. Evaluation of gut mucosal integrity

    qPCR for the expression of key epithelial molecules and cytokines on gut samples

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

  8. 16 S sequencing in the Subjects stools

    The 16S rRNA gene sequencing will be used for the classification and identification of microbes species in subjects stools. Each species will be identified and quantified as a percentage of the total number of identified species in the stools.

    Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Rouxel O, Da Silva J, Beaudoin L, Nel I, Tard C, Cagninacci L, Kiaf B, Oshima M, Diedisheim M, Salou M, Corbett A, Rossjohn J, McCluskey J, Scharfmann R, Battaglia M, Polak M, Lantz O, Beltrand J, Lehuen A. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nat Immunol. 2017 Dec;18(12):1321-1331. doi: 10.1038/ni.3854. Epub 2017 Oct 9. PubMed 28991267 ↗
  • Rouland M, Beaudoin L, Rouxel O, Bertrand L, Cagninacci L, Saffarian A, Pedron T, Gueddouri D, Guilmeau S, Burnol AF, Rachdi L, Tazi A, Mouries J, Rescigno M, Vergnolle N, Sansonetti P, Christine Rogner U, Lehuen A. Gut mucosa alterations and loss of segmented filamentous bacteria in type 1 diabetes are associated with inflammation rather than hyperglycaemia. Gut. 2022 Feb;71(2):296-308. doi: 10.1136/gutjnl-2020-323664. Epub 2021 Feb 16. PubMed 33593807 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Aug 2027, 66 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 66 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jan 2022 → Feb 2022 and primary completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2021
First posted
Sep 23, 2021
StartActual
Feb 14, 2022was Jan 2022
Primary completionEst.
Aug 14, 2027was Aug 2026
CompletionEst.
Aug 14, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 1, 2022→Feb 14, 2022
Oct 27, 2026
Primary completion
Aug 11, 2026→Aug 14, 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Jan 1, 2022→Feb 14, 2022
    Primary completion Aug 11, 2026→Aug 14, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05054361
Collaborators
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Tampere University, Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Sep 23, 2021
Start date
Feb 14, 2022
Primary completion
Aug 14, 2027 (estimated)
Completion
Aug 14, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

jacques beltrand, MD, PhD
Contact
jacques.beltrand@aphp.fr
+33144481545

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion